Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site

Silexion Therapeutics Corp

Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.
SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.
Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.
Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.